Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Megan Molteni reports on discoveries from the frontiers of genomic medicine, ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Analysis suggests consumption at Northumberland site could be 50 times higher than US operator QTS estimates The UK’s largest proposed datacentre is understating the scale of its planned water use, ...
This story is part of the KXAN Data Hub, where numbers help tell the whole story. We’ve created several data-driven stories and databases on topics including weather and climate, politics, education, ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Access detailed historical stock prices, including daily closing prices, for RXRX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback